Halozyme Therapeutics (HALO) 10-Q2011 Q3 Quarterly report

Filed: 8 Nov 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: Aberrant, abundant, acidic, aesthetic, America, anchor, avoiding, boost, buffer, carcinoma, cathepsin, cellulite, circulating, collagen, colorectal, Committee, concentration, conditionally, constricted, contracture, Contrast, defense, degradation, degrading, device, dimpled, discharged, distinct, doctor, Dupuytren, duration, easily, emission, enable, environment, epithelial, exert, extend, fat, fertilization, fiber, fibrosclerotic, finishedHylenexrecombinant, finishHylenexrecombinant, forHylenexrecombinant, Francisco, frozen, glargine, global, harnessing, helical, histochemical, home, HR, Hylenexrecombinant, hypertrophic, imaging, inactive, infrastructure, insertion, judicial, landscape, lifecycle, lived, liver, LP, lung, lysosomal, macromolecular, Magnetic, main, manufacturingHylenexrecombinant, meaningful, medical, Medicinal, medicine, metabolic, metastatic, mild, mildly, mixed, monoclonal, network, neutralized, ofHylenexrecombinant, opportunistic, ourHylenexrecombinant, packagedHylenexrecombinant, packageHylenexrecombinant, panniculopathy, pathologic, pen, perfusion, Peyronie, ph, pharmacy, plasma, positron, pre, procure, prolonged, prophylactic, proteinase, provideHylenex, provideHylenexrecombinant, Qualitative, Quantitative, radiopaque, radiotherapy, ready, rectal, refractory, reintroduceHylenex, reintroduceHylenexrecombinant, Resonance, resorption, restored, returnHylenexrecombinant, scaffolding, scarring, Secondary, septae, serum, short, shoulder, similarly, simplify, smooth, stable, stained, staining, step, suchHylenexrecombinant, superficial, swelling, temporary, tension, theHylenexrecombinant, thought, toHylenexrecombinant, tomography, top, underlyingHylenexrecombinant, Union, unique, untilHylenexrecombinant, upcoming, urography, user, usingHylenex, vitro, vivo, window

Removed: adjuvant, advanced, advantage, alter, cell, commodity, consultation, currency, denominated, depletion, docetaxel, dosing, doxorubicin, employed, freely, frequency, half, infringer, introduce, invest, investigating, investment, linked, liposomal, marketable, maximizing, minute, multicenter, mutual, oppose, optimized, paper, permanently, pharmacodynamic, presence, preserve, progression, quantity, random, Repeat, returned, rich, security, sensitivity, sequence, statute, sustained, titration, vitrofertilization, week

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

HALO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the “Registrant”) on Form 10-Q for the quarter ended September 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gregory I. Frost, Ph.D., Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.


Dated: November 8, 2011		/s/ Gregory I. Frost, Ph.D.
		Gregory I. Frost, Ph.D.
		President and Chief Executive Officer

In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the “Registrant”) on Form 10-Q for the quarter ended September 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kurt A. Gustafson, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.


Dated: November 8, 2011		/s/ Kurt A. Gustafson
		Kurt A. Gustafson
		Vice President, Secretary and Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.